MoonLake Immunotherapeutics (MLTX) Free Cash Flow (2021 - 2026)

MoonLake Immunotherapeutics' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$66.3 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 73.64% year-over-year to -$66.3 million; the TTM figure through Mar 2026 stood at -$224.2 million (down 59.73% YoY), while the FY2025 annual figure was -$196.0 million, down 67.4% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$66.3 million, down from -$58.8 million in the prior quarter.
• The five-year high for Free Cash Flow was -$9.0 million in Q1 2023, with the low at -$66.3 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$20.8 million (2022), against an average of -$28.1 million.
• Peak annual rise in Free Cash Flow reached 67.08% in 2022, while the deepest fall reached 13074.98% in 2022.
• MoonLake Immunotherapeutics' Free Cash Flow stood at -$11.6 million in 2022, then slipped by 6.45% to -$12.3 million in 2023, then slumped by 294.11% to -$48.6 million in 2024, then dropped by 20.85% to -$58.8 million in 2025, then dropped by 12.74% to -$66.3 million in 2026.
• Business Quant data shows MLTX's Free Cash Flow at -$66.3 million in Q1 2026, -$58.8 million in Q4 2025, and -$44.5 million in Q3 2025.